|
Volumn 97, Issue 16, 2005, Pages 1170-1171
|
Should screen-detected breast cancers be managed differently?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
BIOCHEMICAL MARKER;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ESTROGEN RECEPTOR;
PROGESTERONE RECEPTOR;
PROTEIN P53;
AXILLARY LYMPH NODE;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER GRADING;
CANCER RECURRENCE;
CANCER REGISTRY;
CANCER SCREENING;
CANCER STAGING;
CANCER SURVIVAL;
CELL PROLIFERATION;
DISEASE COURSE;
EDITORIAL;
FINLAND;
HUMAN;
INFORMATION PROCESSING;
LYMPH NODE METASTASIS;
MAMMOGRAPHY;
MEDICAL DECISION MAKING;
METASTASIS POTENTIAL;
NORTH AMERICA;
OUTCOMES RESEARCH;
PALPATION;
PATIENT CARE;
PREDICTION;
PRIORITY JOURNAL;
PROGNOSIS;
PROTEIN EXPRESSION;
SYMPTOM;
TUMOR CELL;
TUMOR VOLUME;
ADJUVANT CHEMOTHERAPY;
ADJUVANT THERAPY;
BREAST TUMOR;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
FEMALE;
MASS SCREENING;
METHODOLOGY;
MORTALITY;
NOTE;
PREDICTION AND FORECASTING;
RADIOGRAPHY;
RANDOMIZED CONTROLLED TRIAL;
REGISTER;
RISK FACTOR;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
FEMALE;
FINLAND;
HUMANS;
MAMMOGRAPHY;
MASS SCREENING;
NORTH AMERICA;
PREDICTIVE VALUE OF TESTS;
PROGNOSIS;
RADIOTHERAPY, ADJUVANT;
RANDOMIZED CONTROLLED TRIALS;
REGISTRIES;
RISK FACTORS;
|
EID: 23844557872
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/dji246 Document Type: Editorial |
Times cited : (8)
|
References (7)
|